Myeloma UK and the Structural Genomics Consortium announce open-access collaboration to discover new drug targets for myeloma - Medical News Today
"Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to discover and characterise novel drug targets for myeloma using structural biology and chemical proteomics. In this first partnership of its kind in Europe, Myeloma UK and the SGC have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups. As part of the collaboration, Myeloma UK will support scientists at the SGC to generate biology data and open access research tools to explore potential drug targets, as well as link Myeloma UK clinical and pre-clinical experts into the SGC's open access network. This project reinforces the early-stage component of the Myeloma UK research pipeline, which extends into Phase II/b clinical trials ..."